Pathogenesis of the HIV-TB associated immune reconstitution inflammatory syndrome 4th IAS, Sydney, July 23rd 2007 Robert J Wilkinson Wellcome Senior Fellow,

Slides:



Advertisements
Similar presentations
HIV & TB. Worldwide TB is the most important opportunistic infection in HIV patients – its the commonest killer. Around 20 million people worldwide are.
Advertisements

TB and HIV Management Dr A.L. Pozniak Chelsea and Westminster Hospital London, UK.
ART in HIV-Infected Patients with TB: Research Priorities Group II Facilitator: David Cohn Rapporteur: Soumya Swaminathan.
Tuberculosis and the Immune Reconstitution Inflammatory Syndrome (IRIS) Bob Colebunders.
June 2004 HITCH Training Slide Set #3 Special Considerations in Antiretroviral Therapy.
HIV and TB Co-infection Unit 14 HIV Basics: A Course for Physicians.
Incidence and risks factors of paradoxical tuberculosis-associated IRIS in HIV-infected adults enrolled in the CAMELIA clinical trial ANRS 1295/CIPRA KH001.
Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,
Graeme Meintjes Department of Medicine, University of Cape Town HIV Service, GF Jooste Hospital TB-IRIS Research priorities and update from Kampala workshop.
HIV and TB Co-infection North Dakota HIV Symposium May 19, 2010 David McNamara, M.D. Clinical Assistant Professor of Medicine University of North Dakota.
Immune Reconstitution Inflammatory Syndrome (IRIS)
TB and HIV Coinfection Bruce A. Bush, M.D.
Cryptococcal IRIS: Pathogenesis & Pearls for Clinical Management
Immune Reconstitution Inflammatory Syndrome
Molecular methods for TB drug resistance testing: what is needed? Experience from Khayelitsha, Cape Town, South Africa Helen Cox, PhD, Burnet Institute.
Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.
Integrating HIV and TB services : operational research issues TB/HIV workshop TAC/TAG June 2006 MÉDECINS SANS FRONTIÈRES SOUTH AFRICA UNIVERSITY OF CAPE.
Graeme Meintjes University of Cape Town Imperial College London
A cost-effectiveness evaluation of preventive interventions for HIV-TB in Sub-Saharan Africa (Tanzania): Relevance for neurological infections Lucie Jean-Gilles.
“Don’t tell me TB is under control!” Understanding TB
Results of the CARINEMO ANRS randomized trial comparing the efficacy and safety of nevirapine vs efavirenz for treatment of HIV-TB co-infected patients.
Myeloid cells matter Conclusions. Glut1+ CD14++ CD16+ Associated with inflammatory markers HIV Immune activation HIV-related diseases Joshua Anzigen:
A decentralized model of care for drug-resistant tuberculosis in a high HIV prevalence setting Cheryl McDermid, Helen Cox, Simiso Sokhela, Gilles van Cutsem,
Challenges of service integration: the TB model Linda-Gail Bekker The Desmond Tutu HIV Centre, Faculty of Health Sciences, University of Cape Town, South.
Welcome to UW I-TECH HIV/AIDS Clinical Seminar Series Immune Reconstitution Inflammatory Syndrome Dr. G. Manoharan, M.D., Medical Director, I-TECH India.
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Adult Medical-Surgical Nursing Respiratory Module: Tuberculosis.
The Timing of ART initiation in TB HIV co-infected patients: Impact on IRIS severity 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 20.
HIV/TB – Case Studies David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Health.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
HIV/TB Integration in a Network of Voluntary Counseling/Testing Centers in HAITI Reynold Grand’Pierre MD, Marie Suze Jacquet MD, Jean W. Pape MD PEPFAR.
Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-
High Prevalence Of Subclinical Tuberculosis In HIV-1 Infected Persons Without Advanced Immunodeficiency: Implications For TB Screening Tolu ONI Imperial.
Challenges in adapting chronic HIV/TB services to high mobile populations in Southern Africa Eric Goemaere, MD Médecins Sans Frontières IAS Washington,
Regulatory T cell abnormalities associated with aberrant CD4+ T-cell responses in HIV+ patients with immune reconstitution disease (IRD) Nabila SEDDIKI.
Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.
GERIATRIC TUBERCULOSIS: ISSUES Dr. (Prof.)Vijay Kumar Arora Vice Chancellor Ex Director NITRD Delhi,Ex Director-professor JIPMER, Ex Additional DGHS GOI.
Immune Reconstitution Inflammatory Syndrome (IRIS)
JLF Kock. Overview Introduction Immunopathogenesis Risk factors for IRIS Diagnosis Treatment Review.
TB AND HIV/AIDS THE SITUATION AT BMC Care & Treatment Unit CME, 5/5/20166 PRESENTERS: Dr. Desideris Bernard, Dr. Magawa.
A Call to Action Children – The missing face of AIDS.
The Dynamics of HIV RNA, CD4+ Count and Mycobacterium tuberculosis (Mtb) Antigen Specific Cytokines in TB/HIV Patients Following Successful Tuberculosis.
Increasing Tuberculosis Prevalence in South African Township Associated With Increasing HIV Prevalence Slideset on: Lawn SD, Bekker LG, Middelkoop K, Myer.
Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,
Sarah Al-Obaydi M.B.Ch.B, MPH(c) Fulbright scholar.
TB: The Elispot In The Room Dr Jessica Potter TB Research Registrar Barts Health NHS Trust.
Conflict of Interest No conflicts of interest to declare.
TB AND HIV/AIDS THE SITUATION AT BMC
Tuberculosis (TB) PHCL 442 Lab Discussion 4 Raniah Al-Jaizani M.Sc.
PHASA Conference September 2016
ART was initiated when indicated by WHO and national guidelines
14/02/1396.
TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.
Abstract 791 Impact of Birth PCR on Retention in Care of HIV Exposed Infants in Primary Care Aurelie Nelson1, Laura Trivino Duran1, Tali Cassidy1, Gilles.
Providing ARVs to children in resource limited settings
Chronic immune activation in HIV associated Non Hodgkin lymphoma and the effect of antiretroviral therapy Brian Flepisi University of the Western Cape.
Predictors of antiretroviral treatment associated tuberculosis in Ethiopia: a nested case control study Nebiyu Mesfin, MD.
Dr Dawood Quiz questions.
HIV-associated TB mortality and blocks in the cascade
By: Dr Mirzaei.
Evidence for use of urinary LAM
Cryptococcal Immune Reconstitution Inflammatory Syndrome
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Cryptococcal Immune Reconstitution Inflammatory Syndrome
When to START During an OI
Management of Immune Reconstitution Inflammatory Syndrome (IRIS)
Immune reconstitution inflammatory syndrome (IRIS) associated with Mycobacterium tuberculosis (TB) infection. a) In healthy individuals in response to.
Presentation transcript:

Pathogenesis of the HIV-TB associated immune reconstitution inflammatory syndrome 4th IAS, Sydney, July 23rd 2007 Robert J Wilkinson Wellcome Senior Fellow, Imperial College London and University of Cape Town Programme Leader, MRC National Institute for Medical Research London

MÉDECINS SANS FRONTIÈRES SOUTH AFRICA Contributors Graeme Meintjes Priscilla Mouton Keira Skolimowska Kerryn van Veen Mark Nicol Molebogeng Rangaka Musaed Abrahams Gary Maartens Kevin Rebe Anne O’Garra Chelsea Morroni Katalin Wilkinson Ronnett Seldon David Stead Dominique Pepper Adrian Martineau Gilles van Cutsem Eric Goemaere Steven Lawn

The Western Cape is the richest part of Africa but has the worst TB problem in the world Courtesy Dr Keith Cloete, Provincial administration Cases Registered Entire US UK

Evolution of HIV prevalence rate in Cape Metropole (antenatal VCT results) Metropole Health areas HIV Prevalence (95% CI) Blaauwberg 0.6  ±64.4±3.01.2±17.32 ±3.6 CapeTown Central 3.7  ±611.6±513.7 ± ±3.3 Greater Athlone 6.8  ±410.1± ± ±3.5 Helderberg 19  ± ± ± ±3.0 Khayelitsha 22  ± ± ±3.533 ±3.9 Mitchells Plain 5.4   1.3 4± ±412.9 ±3.55.1±2.1 Gugulethu/Nyanga 16.1  ± ± ± ±3.9 Oostenberg 5.7  ± ± ± ±3.5 South Peninsula 5.9  3.9 6± ± ± ±3.1 Tygerberg Eastern 5.1   ±58.0± ± ±3.5 Tygerberg Western 7.9  ±58.1± ±415.0±3.1 Courtesy of Dr Keith Cloete, PAWC

Tuberculosis in Khayelitsha, South Africa Population: ~350,000 HIV prevalence 33 ± 3.9% (2005) TB incidence rate (2006) ~1600/100,000 ~70% TB is HIV associated 5745 cases found in of 3124 reported deaths in 2006 due to TB (21%)

GF Jooste Referral Area

GF Jooste Hospital serves a population of 1.2 million 8244 people are prescribed antiretroviral treatment in catchment area

Little information on Cause Diagnosis Management An ‘explosion’ of TB-IRIS

TB-IRIS 1 Spectrum and practical case definition 3 Severe TB-IRIS can complicate drug resistant tuberculosis 2 Management with steroids 4 Immunology of TB-IRIS

Nodal enlargement

New pulmonary infiltrate

Cold abscess

Serous effusions

Neurological deterioration

Design of studies Referral to study Excluded or refused consent Severe 1)Resp failure 2)Vital structure compressed 3) TBM Open-label steroids Observational cohort Effusions Pulmonary infiltrate LN Cold abscess Other IRIS manifestations e.g. Bone marrow infiltration RCT 100 patients Observational cohort Steroids at discretion of clinician Immunology and genetic studies Non-IRIS Comparison cohort ‘TB-ART’

Immunological studies Cross-sectional (compare IRIS with non-IRIS groups) Longitudinal within IRIS cohort irrespective of treatment allocation (as IRIS progresses) within TB-ART cohort to document changes should IRIS occur Assays Interferon-gamma ELISpot analysis of PBMC using various antigens 6 and 24 hour restimulation with H37Rv with collection of supernatant and harvesting of RNA for microarray and qRT-PCR 4- and 13- colour FACS (activation status, regulatory and Th17 subsets) Serum cytokines DNA stored. Consent for genetic testing obtained

PPD specificTh1 expansions Granuloma expansion release of inflammatory cytokines TB-IRIS

Antigen selection ESAT-6 38 kDa Acr interim analysis of 184 subjects, data censored 27 May 2007

Cases and controls

Untreated n = 31 p = TB Rx n = 27 p = PPD HIV-TB patient category ART gives rise to large expansions of PPD specific T cells irrespective of whether IRIS occurs IFN-gamma SFC/10 6 PBMC

Responses are directed to several categories of antigen p = p = 0.05 IFN-gamma SFC/10 6 PBMC 38 kDa IRISTB Rx HIV-TB patient category H37Rv IRISTB Rx HIV-TB patient category IFN-gamma SFC/10 6 PBMC ESAT-6 IRISUntreatedTB Rx HIV-TB patient category Acr 1 IRISUntreatedTB Rx HIV-TB patient category

Longitudinal analysis of TB patients starting ART n=55 Proportion responding to H37Rv week 0week 2week 4week 8 IRIS Percentage responders Non-IRIS Proportion responding to PPD Percentage responders week 0week 2week 4week 8 IRIS Non-IRIS

Longitudinal analysis of TB patients starting ART week 0At diagnosisweek 0week 2 IRISNon-IRIS Interferon-  SFC/10 6 PBMC p = 0.01 p = 0.34

M. Tuberculosis induced proliferation, activation and regulation CD4 + CD71 + Marker Percentage CD3 cells positive CD4 + DR + CD8 + CD71 + CD8 + DR + CD4 + FoxP3 + unstimulated CD4 + FoxP3 + stimulated TB-IRIS n=10 Day 14 non-IRIS n=10

Conclusions ART mediated immune restoration during therapy of active TB is associated with a substantial early expansion of TB antigen specific IFN-  secreting T cells TB therapy in the absence of ART is also associated with restoration of responses to some antigens An increased response to heat killed bacilli best associates with IRIS The numbers of regulatory T cells did not differ between IRIS and non- IRIS subjects IRIS is clinically significant and very heterogenous. Studies need to be adequately powered.

Generalisability: Protective and pathogenic immune responses in tuberculosis Robert Koch Thinking hard about IRIS

Thank you

Corticosteroids have little effect on T cell expansions ESAT-6 PPD Days since onset IFN gamma SFC/million PBMC New cervical LN 21 days after starting HAART in lady with Cult. +ve PTB. Prescribed study drug Neurological deterioration Open label Prednisone Resolution of symptoms

Too much killing of M. tuberculosis? Serum HNP1-3 ng/ml Martineau et al. J. Clin. Invest. in press RLU/ml

Who gets IRIS?

Why the ELISpot results differ from Bourgarit et al. PPD Week 0Week 2Week 4Week 8IRIS IFN-gamma SFC/10 6 PBMC

When and what form of IRIS?

Challenges in diagnosis No diagnostic test; diagnosis of exclusion ALTERNATIVE DIAGNOSIS Bacterial infections Fungal infection PCP NTM Lymphoma Kaposi’s sarcoma Drug resistance 14/141 in Cape Town cohort of TB-IRIS suspects had MDR or Rifampicin monoresistance DRUG REACTION especially if hepatic involvement

MDR-TB-IRIS overlap syndrome Drug resistance and TB-IRIS 14/141 had drug resistance (10%) –3 known to have MDR –2 known to have Rif mono-resistance –1 known to have INH mono-resistance –6 presented with TB IRIS then MDR diagnosed* –2 presented with TB IRIS then Rif mono-resistance diagnosed* * Most of these patients reported some (or complete) improvement on TB Rx and all reported symptomatic deterioration after HAART, some required steroids Fastplaque Rif resistance assay being used to expedite diagnosis 5 died